DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues

• Justin M. Craig,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Natalie Vena,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Shakti Ramkissoon,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

  ⨯
• Ahmed Idbaih,

  Affiliation Hopital Pitie Salpetriere, Service de Neurologie Mazarin, Paris, France

  ⨯
• Shaun D. Fouse,

  Affiliation Department of Neurosurgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Memet Ozek,

  Affiliation Division of Pediatric Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey

  ⨯
• Aydin Sav,

  Affiliation Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey

  ⨯
• D. Ashley Hill,

  Affiliation Department of Pathology, Children’s National Medical Center, Washington, District of Columbia, United States of America

  ⨯
• Linda R. Margraf,

  Affiliation Department of Pathology, The University of Texas Southwestern Medical Center, Children’s Medical Center, Dallas, Texas, United States of America

  ⨯
• Charles G. Eberhart,

  Affiliation Departments of Pathology, Oncology and Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

  ⨯
• Mark W. Kieran,

  Affiliations Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pediatrics, Boston Children’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Andrew D. Norden,

  Affiliations Department of Neurology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Patrick Y. Wen,

  Affiliations Department of Neurology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Massimo Loda,

  Affiliations Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Sandro Santagata,

  Affiliations Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Department of Pathology, Boston Children’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Keith L. Ligon ,

  * E-mail: keith_ligon@dfci.harvard.edu (KL); aligon@rics.bwh.harvard.edu (AL)

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Department of Pathology, Boston Children’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
•  [ ... ],
• Azra H. Ligon

  * E-mail: keith_ligon@dfci.harvard.edu (KL); aligon@rics.bwh.harvard.edu (AL)

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• [ view all ]
• [ view less ]